Anktiva
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Long COVID
Conditions
Long COVID, Long COVID Syndrome, Long Covid 19
Trial Timeline
Sep 4, 2025 → Jul 1, 2026
NCT ID
NCT07123727About Anktiva
Anktiva is a phase 2 stage product being developed by ImmunityBio for Long COVID. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07123727. Target conditions include Long COVID, Long COVID Syndrome, Long Covid 19.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07123727 | Phase 2 | Recruiting |
Competing Products
16 competing products in Long COVID
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ensitrelvir | Shionogi | Phase 2 | 52 |
| TBM100 | Novartis | Approved | 85 |
| GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Placebo + Ranolazine | Gilead Sciences | Phase 2 | 51 |
| GS-6615 | Gilead Sciences | Phase 1 | 32 |
| Eleclazine + Eleclazine placebo | Gilead Sciences | Phase 3 | 76 |
| Nirmatrelvir + Ritonavir + Placebo | Pfizer | Phase 2 | 51 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) | ImmunityBio | Phase 2 | 49 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
Other Products from ImmunityBio
NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelPhase 3
74
N-803 + Tislelizumab + DocetaxelPhase 3
74
Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)Phase 3
74
N-803 and BCG + N-803Phase 2/3
62
hAd5-S-Fusion+N-ETSD + Placebo (0.9% (w/v) saline)Phase 2/3
62